Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CMVPepVax in Allogeneic Hematopoietic Stem Cell Transplant Recipients
NCT02396134Phase 2Completed
- Sponsor
- City of Hope
- Start
- Jun 2015
- Primary completion
- Mar 2018
- Countries
- 1
01
Overview
A Phase 2 trial of CMVpp65-A*0201 peptide in cytomegalovirus infection (CMV), sponsored by City of Hope. Started Jun 2015; status: completed.
02
Drugs
CMVpp65-A*0201 peptide
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT02396134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02396134.